Richard Pazdur (vis AACR)

Roche, Bris­tol My­ers, and Mer­ck prep de­fense for 6 ‘dan­gling’ PD-(L)1 ac­cel­er­at­ed ap­provals, even though they failed con­fir­ma­to­ry tri­als

Should 6 sig­nif­i­cant ac­cel­er­at­ed ap­provals for 3 of the top PD-(L)1s on the mar­ket get yanked or stand un­changed, even though they failed key re­quired …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.